Japan's Ministry Continues Safety Measures On AstraZeneca's Iressa
This article was originally published in PharmAsia News
Executive SummaryJapan's Ministry of Health, Labor and Welfare's Pharmaceutical Safety Committee decided August 1 to continue current safety measures and side effects monitoring regarding AstraZeneca's lung cancer drug Iressa (gefitinib). The committee also summarized and confirmed the drug's clinical benefits. Since last February, the committee has conducted trials comparing gefitinib with other AstraZeneca cancer drugs, and the committee concluded that the results need further analyzing. Iressa has been the center of attention since serious side effects were reported in Japan. (Click here for more - Japanese language
You may also be interested in...
Hiring travails, inspection pre-announcement, lack of translators highlighted in congressional hearing on FDA foreign inspections.
The court included its decision on Amarin’s ’s petition for a writ of certiorari among the single-line denials of nearly 200 appeals to consider decisions in civil litigation and convictions in criminal cases. However, Amarin still eyes curbing competition from omega-3 supplements.
Senate's Over-the-Counter Monograph Safety, Innovation, and Reform Act goes next for consideration by House, which has had a bill by the same title on its floor for a vote since it was passed by Energy and Commerce Committee in late June.